United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally.
No risks detected for UTH from our risk checks.
Fair value with moderate growth potential.
Share Price & News
How has United Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: UTH has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: UTH underperformed the German Biotechs industry which returned -8.1% over the past year.
Return vs Market: UTH exceeded the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is United Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is United Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: UTH (€87.5) is trading below our estimate of fair value (€212.43)
Significantly Below Fair Value: UTH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: UTH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: UTH is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate UTH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: UTH is good value based on its PB Ratio (1.5x) compared to the DE Biotechs industry average (3.6x).
How is United Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UTH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: UTH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: UTH's is expected to become profitable in the next 3 years.
Revenue vs Market: UTH's revenue (2.4% per year) is forecast to grow slower than the German market (4.1% per year).
High Growth Revenue: UTH's revenue (2.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: UTH's Return on Equity is forecast to be low in 3 years time (12%).
How has United Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: UTH is currently unprofitable.
Growing Profit Margin: UTH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: UTH is unprofitable, and losses have increased over the past 5 years at a rate of -21.3% per year.
Accelerating Growth: Unable to compare UTH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UTH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: UTH has a negative Return on Equity (-3.76%), as it is currently unprofitable.
How is United Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: UTH's short term assets ($1.9B) exceed its short term liabilities ($463.0M).
Long Term Liabilities: UTH's short term assets ($1.9B) exceed its long term liabilities ($670.0M).
Debt to Equity History and Analysis
Debt Level: UTH's debt to equity ratio (30.6%) is considered satisfactory.
Reducing Debt: UTH's debt to equity ratio has increased from 10.2% to 30.6% over the past 5 years.
Inventory Level: UTH has a high level of physical assets or inventory.
Debt Coverage by Assets: UTH's debt is covered by short term assets (assets are 2.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: UTH has been profitable on average in the past, therefore cash runway is not a concern.
Forecast Cash Runway: UTH has been profitable on average in the past, therefore cash runway is not a concern.
What is United Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate UTH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate UTH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if UTH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if UTH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of UTH's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Martine Rothblatt (64yo)
Dr. Martine A. Rothblatt, Ph.D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser ...
CEO Compensation Analysis
Compensation vs Market: Martine's total compensation ($USD16.04M) is above average for companies of similar size in the German market ($USD3.79M).
Compensation vs Earnings: Martine's compensation has been consistent with company performance over the past year.
|President & COO||3.67yrs||US$6.61m||0.0039% $149.2k|
|CFO & Treasurer||5yrs||US$5.24m||0.0017% $66.7k|
|Executive VP||24.17yrs||US$5.30m||0.082% $3.2m|
|Head of Investor Relations||no data||no data||no data|
|Senior Vice President of Strategic Operations & Logistics||no data||no data||no data|
|Executive VP of Technical Operations||10.83yrs||no data||no data|
|Vice President of Product Development||no data||no data||no data|
Experienced Management: UTH's management team is seasoned and experienced (5 years average tenure).
|Independent Director||18.17yrs||US$479.08k||0.012% $462.9k|
|Independent Director & Member of the Scientific Advisory Board||17.42yrs||US$510.53k||0.016% $628.8k|
|Non Independent Director & Member of the Scientific Advisory Board||no data||US$480.53k||no data|
|Vice Chairman & Lead Independent Director||no data||US$568.76k||0.0030% $114.7k|
|Independent Director||16.67yrs||US$518.76k||0.0022% $86.1k|
|Independent Director||10.17yrs||US$494.08k||0.060% $2.3m|
|Member of The Scientific Advisory Board||no data||no data||no data|
|Independent Director||10.83yrs||US$520.53k||0.0086% $331.4k|
|Independent Director||5.25yrs||US$478.76k||no data|
Experienced Board: UTH's board of directors are seasoned and experienced ( 16.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
United Therapeutics Corporation's company bio, employee growth, exchange listings and data sources
- Name: United Therapeutics Corporation
- Ticker: UTH
- Exchange: DB
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.260b
- Listing Market Cap: US$3.877b
- Shares outstanding: 43.88m
- Website: https://www.unither.com
Number of Employees
- United Therapeutics Corporation
- 1040 Spring Street
- Silver Spring
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|UTHR||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Jun 1999|
|UTH||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jun 1999|
|UTH||BRSE (Berne Stock Exchange)||Yes||Common Shares||CH||CHF||Jun 1999|
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company’s commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 21:54|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.